Paula D. Ryan, MD, PhD, Joins Fox Chase's Department of Medical Oncology

PHILADELPHIA (February 18, 2011) – Paula D. Ryan, MD, PhD, has joined Fox Chase Cancer Center as an attending physician for the department of medical oncology. She specializes in treating patients with all stages of breast cancer, with a focus on breast cancers that are locally advanced and metastatic. Ryan has particular interest in coordinating the management of patients requiring complex care. In addition, she is committed to clinical research with a special interest in developing novel strategies and agents for the treatment of metastatic breast cancer.

“For me, it is a privilege to care for patients with breast cancer, and I am excited to join the staff at Fox Chase,” Ryan says. “My goal is to provide each of my patients with individualized, compassionate, state-of-the-art care.”

Ryan comes to Fox Chase from Massachusetts General Hospital Cancer Center and Dana Farber/Harvard Cancer Center in Boston, where she practiced in the breast oncology group for 10 years. She also served as medical director of the Breast and Ovarian Cancer Genetics and Risk Assessment Program at Massachusetts General and assistant professor of medicine at Harvard Medical School.

Ryan practices in the Women’s Cancer Center at Fox Chase. “I feel the best care for patients with breast cancer is achieved with a multidisciplinary team that works together to develop an individualized, comprehensive treatment plan conducted in a supportive environment for patients and their loved ones,” she says. “The Women’s Cancer Center provides the ideal environment to achieve this goal.”

Ryan earned a PhD in biochemistry at the University of Rochester Medical Center in Rochester, NY, where she later received her MD. She completed her residency in internal medicine, serving as chief resident in her final year, as well as a fellowship in medical oncology at Duke University Medical Center in Durham, NC.

A member of the American Society of Clinical Oncology, Ryan also serves on the breast cancer risk reduction panel of the National Comprehensive Cancer Network. In addition, she serves as an ad-hoc reviewer for various professional journals, including The New England Journal of MedicineThe Oncologist, and the Journal of Clinical Oncology.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427